{"id":35914,"date":"2025-06-24T23:05:32","date_gmt":"2025-06-24T15:05:32","guid":{"rendered":"https:\/\/flcube.com\/?p=35914"},"modified":"2025-06-24T23:10:29","modified_gmt":"2025-06-24T15:10:29","slug":"simcere-halts-rd-on-alzheimers-drug-candidates-amid-pipeline-setbacks","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35914","title":{"rendered":"Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks"},"content":{"rendered":"\n

Simcere Pharmaceutical Group (HKG: 2096<\/a>) has reportedly discontinued research and development of its Alzheimer’s disease (AD) drug candidates, according to recent media reports. This decision comes after the company’s partnership with Germany-based Vivoryon Therapeutics yielded underwhelming results. <\/p>\n\n\n\n

Background on Collaboration<\/strong>
In June 2021, Simcere established a collaboration with Vivoryon to develop and commercialize two AD therapies in Greater China: Varoglutamstat, an oral small-molecule QPCT inhibitor targeting N3pE amyloid, and PBD-C06, a monoclonal N3pE antibody.<\/p>\n\n\n\n

Clinical Setbacks<\/strong>
In March 2024, Vivoryon released data from the Phase IIb VIVIAD study, which showed that Varoglutamstat failed to demonstrate significant efficacy in early AD patients. Varoglutamstat received clinical study approval in China in February 2022 and remains “ongoing, not yet recruiting.” Meanwhile, PBD-C06 has shown no substantial progress since the collaboration began.<\/p>\n\n\n\n

Current Status<\/strong>
While these pipeline assets have been removed from Simcere’s official website and annual reports, company insiders claim the AD projects are “not officially terminated.”-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer’s disease…<\/p>\n","protected":false},"author":1,"featured_media":35916,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,6],"tags":[17,1099,271,4178],"class_list":["post-35914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-rd","tag-clinical-trial-results","tag-hkg-2096","tag-simcere-pharmaceutical","tag-vivoryon-therapeutics"],"yoast_head":"\nSimcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer's disease (AD) drug candidates, according to recent media reports. This decision comes after the company's partnership with Germany-based Vivoryon Therapeutics yielded underwhelming results.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35914\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer's disease (AD) drug candidates, according to recent media reports. This decision comes after the company's partnership with Germany-based Vivoryon Therapeutics yielded underwhelming results.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35914\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T15:05:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T15:10:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks\",\"datePublished\":\"2025-06-24T15:05:32+00:00\",\"dateModified\":\"2025-06-24T15:10:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914\"},\"wordCount\":172,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2405-1.webp\",\"keywords\":[\"Clinical trial results\",\"HKG: 2096\",\"Simcere Pharmaceutical\",\"Vivoryon Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\",\"R&D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35914#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35914\",\"name\":\"Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2405-1.webp\",\"datePublished\":\"2025-06-24T15:05:32+00:00\",\"dateModified\":\"2025-06-24T15:10:29+00:00\",\"description\":\"Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer's disease (AD) drug candidates, according to recent media reports. This decision comes after the company's partnership with Germany-based Vivoryon Therapeutics yielded underwhelming results.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35914\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2405-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2405-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35914#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks - Insight, China's Pharmaceutical Industry","description":"Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer's disease (AD) drug candidates, according to recent media reports. This decision comes after the company's partnership with Germany-based Vivoryon Therapeutics yielded underwhelming results.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35914","og_locale":"en_US","og_type":"article","og_title":"Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks","og_description":"Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer's disease (AD) drug candidates, according to recent media reports. This decision comes after the company's partnership with Germany-based Vivoryon Therapeutics yielded underwhelming results.","og_url":"https:\/\/flcube.com\/?p=35914","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-24T15:05:32+00:00","article_modified_time":"2025-06-24T15:10:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35914#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35914"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks","datePublished":"2025-06-24T15:05:32+00:00","dateModified":"2025-06-24T15:10:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35914"},"wordCount":172,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35914#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405-1.webp","keywords":["Clinical trial results","HKG: 2096","Simcere Pharmaceutical","Vivoryon Therapeutics"],"articleSection":["Company","Drug","R&D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35914#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35914","url":"https:\/\/flcube.com\/?p=35914","name":"Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35914#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35914#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405-1.webp","datePublished":"2025-06-24T15:05:32+00:00","dateModified":"2025-06-24T15:10:29+00:00","description":"Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer's disease (AD) drug candidates, according to recent media reports. This decision comes after the company's partnership with Germany-based Vivoryon Therapeutics yielded underwhelming results.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35914#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35914"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35914#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405-1.webp","width":1080,"height":608,"caption":"Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35914#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35914"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35914\/revisions"}],"predecessor-version":[{"id":35919,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35914\/revisions\/35919"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35916"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}